Drugs / MTX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03855007 | Jan 2016 → Sep 2023 | rheumatoid arthritis | Qilu Hospital of Shandong University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03855007 ↗ |
| Route | Oral | “7.5mg to 15mg, po, once per week (Qw)” NCT03855007 ↗ |